DOCSLIB.ORG

Impfstoffkandidaten Gegen SARS-Cov-2, Die Sich Aktuell In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Impfstoffkandidaten Gegen SARS-Cov-2, Die Sich Aktuell In Impfstoffkandidaten gegen SARS-CoV-2, die sich aktuell in klinischer Prüfung befinden (Vereinfachte Übersicht, kein Anspruch auf Vollständigkeit, alle Angaben ohne Gewähr; Stand: 12.03.2021; die Reihenfolge der Darstellung wurde der Abbildung Strategien der SARS-CoV-2- Impfstoffentwicklung angeglichen sowie eine weitere Kategorie hinzugefügt; inhaltliche Änderungen im Vergleich zur Vorversion sind farblich gekennzeichnet) IMPFSTOFF-PLATTFORM/- ENTWICKLER KLINISCHE STUDIEN ART (HAUPTSITZ) (STUDIENORT)* VIRUSBASIERTE IMPFSTOFFE Inaktivierter Virusimpfstoff Wuhan Institute of Biological Phase 1/2 (China) (SARS-CoV-2) Products/Sinopharm (China) Phase 3 (UAE) Phase 3 (Marokko) Phase 3 (Peru) Phase 3 (Bahrain, Ägypten, Jordanien, UAE) Inaktivierter Virusimpfstoff Beijing Institute of Biological Phase 1/2 (China) BBIBP-CorV (SARS-CoV-2) Products/Sinopharm (China) Phase 3 (UAE) Phase 3 (Argentinien) Phase 3 (Bahrain, Ägypten, Jordanien, UAE) Inaktivierter Virusimpfstoff Sinovac Phase 1/2 (China) CoronaVac (China) Phase 1/2 (China) (SARS-CoV-2) Phase 1/2 (China) Phase 2 (Brasilien, immunsupprimierte Patienten) Phase 3 (Brasilien) Phase 3 (Indonesien) Phase 3 (Türkei) Phase 3 (China) Phase 3 (Chile) Phase 4 (Brasilien; Rekru- tierung noch nicht begonnen) Phase 4 (Brasilien) Phase 4 (Hong Kong, Patienten mit chron. Lebererkrankungen; Rekrutierung noch nicht begonnen) Inaktivierter Virusimpfstoff Institute of Medical Biology, Phase 1 (China) (SARS-CoV-2) Chinese Academy of Medical Phase 1/2 (China) Sciences (China) Nationale Lenkungsgruppe Impfen, www.nali-impfen.de Stand: 12.03.2021 Phase 3 (Brasilien, Malaysia; Rekrutierung noch nicht begonnen) Inaktivierter Virusimpfstoff Bharat Biotech Phase 1/2 (Indien) BBV152 (Indien) Phase 1/2 (Indien) (SARS-CoV-2) Phase 3 (Indien) Phase 3 (Indien) Inaktivierter Virusimpfstoff Research Institute for Biological Phase 1/2 (Kasachstan) QazCovid-in (SARS-CoV-2) Safety Problems (Kasachstan) Phase 3 (Kasachstan) Inaktivierter Virusimpfstoff Shenzhen Kangtai Biological Phase 1 (China) (SARS-CoV-2) Products Co., Ltd /Beijing Phase 1/2 (China) Minhai Biotechnology Co., Ltd (China) Inaktivierter Virusimpfstoff Valneva, National Institute of Phase 1/2 (UK) VLA2001 Health Research (UK) (SARS-CoV-2) Inaktivierter Virusimpfstoff Erciyes University (Türkei) Phase 1 (Türkei) ERUCOV-VAC (SARS-CoV-2) Inaktivierter Virusimpfstoff Shifa Pharmed Industrial Co Phase 1 (Iran) Shif-Pharmed (SARS-CoV-2) (Iran) Abgeschwächter Codagenix/Serum Institute of Phase 1 (UK) Virusimpfstoff COVI-VAC India (USA, Indien) (Codon-deoptimiertes SARS- CoV-2, lebend-attenuiert) PROTEINBASIERTE IMPFSTOFFE Protein-/Protein- Novavax Phase 1/2 (Australien) Untereinheitenimpfstoff (USA) Phase 2 (Südafrika) NVX-CoV2373 (rekomb. SARS- Phase 3 (UK) CoV-2 Glycoprotein, adjuvantiert mit Matrix-M) Phase 3 (USA, Mexiko, Puerto Rico) Protein-/Protein- Clover Biopharmaceuticals Phase 1 (Australien) Untereinheitenimpfstoff Inc./GSK/Dynavax Phase 2/3 (Belgien, Brasilien, SCB-2019 (rekomb. SARS-CoV- (China/UK/USA) Kolumbien, Dominik. Republik, 2-Spikeprotein, Trimer, Deutschland, Nepal, Panama, adjuvantiert) Philippinen, Polen, Südafrika; Rekrutierung noch nicht begonnen) Protein-/Protein- Anhui Zhifei Longcom Phase 1 (China) Untereinheitenimpfstoff Biopharmaceutical/Institute of Phase 1 (China) ZF2001 Microbiology, Chinese Academy Phase 1 (China) (rekomb. of Sciences (China) Rezeptorbindedomäne des Phase 1/2 (China) Phase 2 (China) Nationale Lenkungsgruppe Impfen, www.nali-impfen.de Stand: 12.03.2021 SARS-CoV-2-Spikeproteins, Phase 3 (China) Dimer, adjuvantiert) Phase 3 (China) Protein-/Protein- Vaxine Pty Ltd/Medytox Phase 1 (Australien) Untereinheitenimpfstoff (Australien/Südkorea) COVAX19 (rekomb. SARS-CoV- 2-Spikeprotein, adjuvantiert mit AdvaxTM) Protein-/Protein- University of Phase 1 (Australien) Untereinheitenimpfstoff Queensland/CSL/Seqirus (SARS-CoV-2-Spikeprotein, (Australien) molecular clamp stabilisiert, adjuvantiert mit MF59) Protein-/Protein- Kentucky Bioprocessing Phase 1/2 (USA) Untereinheitenimpfstoff (USA) KBP-COVID-19 Protein-/Protein- Sanofi Pasteur/GSK (Frankreich, Phase 1/2 (USA) Untereinheitenimpfstoff Großbritannien) Phase 2 (USA) (rekomb. SARS-CoV-2-Protein, Phase 3 (Kenia; Rekrutierung adjuvantiert und nicht noch nicht begonnen) adjuvantiert) Protein-/Protein- Medigen Vaccine Biologics Phase 1 (Taiwan) Untereinheitenimpfstoff Corporation/NIAID/Dynavax Phase 2 (Taiwan, Vietnam) MVC-COV1901 (SARS-CoV-2- (Taiwan, USA) Spike-protein, adjuvantiert mit CpG 1018) Protein-/Protein- Instituto Finlay de Vacunas Phase 1 FR-1 (Kuba) Untereinheitenimpfstoff (Kuba) Phase 1/2 FR-1 (Kuba) FINLAY-FR-1 (adjuvantiert) Phase 1 FR-2 (Kuba) und FINLAY-FR-2 (nicht adjuvantiert) Phase 2 FR-2 (Kuba) Phase 3 FR-2 und FR-1 (Kuba; Rekrutierung noch nicht begonnen) Protein-/Protein- Federal Budgetary Research Phase 1/2 (Russland) Untereinheitenimpfstoff Institution State Research Phase 3 (Russland) EpiVacCorona (chem. synth. Center of Virology and SARS-CoV-2-Protein, konjugiert Biotechnology (FBRI SRC VB mit Carrierprotein, „VECTOR“) (Russland) adjuvantiert mit Aluminium- Hydroxid) Protein-/Protein- West China Hospital, Sichuan Phase 1 (China) Untereinheitenimpfstoff University (China) Phase 2 (China) (rekomb. Phase 2 (China; Rekrutierung Rezeptorbindedomäne des noch nicht begonnen) SARS-CoV-2-Spikeproteins, Nationale Lenkungsgruppe Impfen, www.nali-impfen.de Stand: 12.03.2021 adjuvantiert mit Aluminium- Hydroxid) Protein-/Protein- Adimmune Corporation (Taiwan) Phase 1 (Taiwan) Untereinheitenimpfstoff AdimrSC-2f (rekomb. Rezeptorbindedomäne des SARS-CoV-2-Spikeproteins, mit/ohne Adjuvans) Protein-/Protein- Center for Genetic Engineering Phase 1/2 (Kuba; Rekrutierung Untereinheitenimpfstoff and Biotechnology (CIGB) (Kuba) noch nicht begonnen) (rekomb. Rezeptorbindedomäne des SARS-CoV-2-Spikeproteins, nasale Applikation) Protein-/Protein- Center for Genetic Engineering Phase 1/2 (Kuba; Rekrutierung Untereinheitenimpfstoff and Biotechnology (CIGB) (Kuba) noch nicht begonnen) CIGB-66 (rekomb. Rezeptor- bindedomäne des SARS-CoV-2- Spikeproteins, adjuvantiert) Protein-/Protein- Nanogen Pharmaceutical Phase 1/2 (Vietnam) Untereinheitenimpfstoff Biotechnology (Vietnam) Nanocovax (rekomb. SARS- CoV-2-Spikeprotein, adjuvantiert) Protein-/Protein- Shionogi (Japan) Phase 1/2 (Japan) Untereinheitenimpfstoff S- 268019 (rekomb. SARS-CoV-2- Spikeprotein, hergestellt mittels eines Baculovirus- Expressionssystems, adjuvantiert) Protein-/Protein- Biological E Ltd. (Indien) Phase 1/2 (Indien) Untereinheitenimpfstoff (Rezeptorbindedomäne von SARS-CoV-2) Protein-/Protein- Vaccine Formulation Insitute Phase 1/2 (Kanada; Untereinheitenimpfstoff (VFI), Seppic, Vaccine and Rekrutierung noch nicht COVAC-1/2 (rekomb. SARS- Infectious Deiseas Organization begonnen) CoV-2-Spikeprotein (Teil S1); (VIDO) (Kanada) COVAC-1: nicht adjuvantiert, COVAC-2: adjuvantiert) Protein-/Protein- Razi Vaccine and Serum Phase 1 (Iran) Untereinheitenimpfstoff Razi Research Institute (Iran) Cov Pars (rekomb. SARS-CoV- 2-Spikeprotein) Nationale Lenkungsgruppe Impfen, www.nali-impfen.de Stand: 12.03.2021 Protein-/Protein- SK Bioscience Co., Ltd. Phase 1 (Südkorea) Untereinheitenimpfstoff (Südkorea) NBP2001 (adjuvantiert) Protein-/Protein- Walter Reed Army Institute of Phase 1 (Rekrutierung noch Untereinheitenimpfstoff Research (USA) nicht begonnen) SpFN (SARS-CoV-2 Spikeprotein-Ferretin- Nanopartikel, adjuvantiert) Protein-/Protein- EuBiologics Co., Ltd. (Südkorea) Phase 1/2 (Südkorea) Untereinheitenimpfstoff EuCorVac-19 (rekomb. SARS- CoV-2-Spikeprotein, adjuvantiert) Virusähnliche Partikel Medicago Inc./Université Laval Phase 1 (Kanada) (aus Pflanzen, adjuvantiert) (Kanada) Phase 2 (USA, Kanada) Phase 2/3 (Kanada) Virusähnliche Partikel Accelagen Pty/Serum Institute Phase 1/2 (Australien) (Rezeptorbindedomäne des of India (UK, Indien) Phase 1/2 (Australien) SARS-CoV-2-Spikeprotein auf HBsAG VLPs; adjuvantiert und ohne Adjuvans) Virusähnliche Partikel SK Bioscience Co., Ltd. Phase 1/2 (Südkorea) GBP510 (Südkorea) (rekomb. Rezeptorbindedomäne des SARS-CoV-2-Spikeprotein auf Nanopartikeln, adjuvantiert) Virsähnliche Partikel VBI- VBI Vaccines Inc. Phase 1/2 (Kanada; 2902a (modifiziertes SARS- (USA) Rekrutierung noch nicht CoV-2-Spikeprotein auf begonnen) umhüllten virusänlichen Partikeln, adjuvantiert) Multi-Peptid Impfstoff Universitätsklinikum Tübingen Phase 1 (Deutschland) CoVac-1 (Deutschland) (von SARS-CoV-2-abgeleitete Peptide in Kombination mit dem TLR1/2-Liganden XS15; subkutane Applikation) Multi-Peptid Impfstoff UB- Covaxx Phase 1 (Taiwan) 612 (von SARS-CoV-2- (USA) Phase 2 (Taiwan) abgeleitete Peptide) Phase 2/3 (Rekrutierung noch nicht begonnen) Nationale Lenkungsgruppe Impfen, www.nali-impfen.de Stand: 12.03.2021 COVID-19-spezifisches Akston Biosciences Inc., Phase 1/2 (Niederlande; Fc-Fusionsprotein Vaccine University Medical Center Rekrutierung noch nicht Groningen (Niederlande) begonnen) IMPFSTOFFE AUS VIRALEN VEKTOREN Nicht-replizierender viraler Universität Oxford/ Phase 1/2 (UK) Vektor ChAdOx1 nCOV-19 Astra Zeneca Phase 1/2 (Südafrika) (auf Basis des Adenovirus Typ (UK) Phase 1/2 (Japan) 63, das in Schimpansen vorkommt und daraus isoliert Phase 1/2 (Kenia) wurde) Phase 1/2 (Rekrutierung noch nicht begonnen) Phase 2 (Aserbaidschan; Rekrutierung noch nicht begonnen) Phase 2 (UK, Alter 6 bis 17 Jahre) Phase 2 (UK) Phase 2/3 (UK) Phase 2/3 (Indien) Phase 3 (Brasilien) Phase 3 (USA, Chile, Peru) Phase 3 (Russland) Phase 4 (Dänemark) Phase 4 (Hong Kong, Patienten mit chron. Lebererkrankungen;
Load more

Recommended publications
  • Vaccination What Is Vaccination?
    VACCINATION WHAT IS VACCINATION? Vaccination is a simple, safe, and effective way of protecting people against harmful diseases, before they come into contact with them. Makes your immune system stronger. Vaccines train your immune system to create antibodies. SOURCE : World Health Organization Why You Should Get Vaccinated? COVID-19 vaccines are safe and effective. When we get vaccinated, we aren’t just protecting ourselves, but also those around us. Helps to reduce the spread of disease. SOURCE : World Health Organizations Are Vaccines Safe? Vaccination is safe. The benefits of vaccination greatly outweigh the risks, and many more illnesses and deaths would occur without vaccines. SOURCE : World Health Organization Side Effects Of Vaccines Like any medicine, vaccines can cause mild side effects, such as a low- grade fever, or pain or redness at the injection site. Severe or long-lasting side effects are extremely rare. Vaccines are continually monitored for safety, to detect rare adverse events. SOURCE : World Health Organization Types Of Vaccines In India 1. Covaxin 2. Covishield 3. ZyCoV-D 4. Sputnik 5. BBV154 – Intranasal Vaccine 6. Moderna 7. Pfizer SOURCE : Indian Council Of Medical Research Details About Covaxin Covaxin is an inactivated vaccine which means that it is made up of killed coronaviruses, making it safe to be injected into the body. When administered, immune cells can still recognise the dead virus, prompting the immune system to make antibodies against the pandemic virus. The two doses are given four weeks apart. The vaccine can be stored at 2C to 8C. SOURCE : BBC Details About Covishield The vaccine is made from a weakened version of a common cold virus (known as an adenovirus) from chimpanzees.
    [Show full text]
  • Editorial 10.5005/Ijmb-24-3-Iv
    Editorial 10.5005/ijmb-24-3-iv COVID-19 Vaccines: Lets Go for It SARS CoV-2, also christened as COVID-19 is an acute respiratory illness caused by a novel coronavirus which originated from Wuhan China in 2019 and within a short span affected virtually each and every country around the globe, throwing healthcare preparedness and economy out of gear. The world was faced with a pandemic leading to overcrowded hospitals and overflowing mortuaries. Lockdowns imposed in countries jeopardized routine life never to normalize again. India has been among the top three countries with the maximum number of afflicted people. Thankfully , our statistics with respect to mortality is better as compared to the western world. The last year 2020 was completely COVIDISED if we may say so. The world economy is in doldrums and the health infrastructure is overstretched and fatigued. Everytime we feel that the disease is under control, the virus cleverly mutates to become more infective and develops increased ability to escape the immune surveillance. Efforts to develop a vaccine against this scourge were initiated at a war footing across the globe. A number of vaccines were approved for emergency use since the scientific committee didn’t have the time to wait further. In India, two vaccines- Covaxin and Covishield have been approved by the Government of India for mass vaccination. The mammoth program was initiated with first preference for the healthcare workers and frontline warriors. In the next phases, elderly population followed by the rest of the population in a phased manner was planned. It is really incredible and praiseworthy about the immaculate planning and implementation of the initiative in our country where the diversity is both a boon as well as bane.
    [Show full text]
  • Progress in the Development of Potential Therapeutics and Vaccines Against COVID-19 Pandemic
    Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) Volume 5 Issue 7 July 2021 Review Article Progress in the Development of Potential Therapeutics and Vaccines against COVID-19 Pandemic Abhishek Kumar Yadav, Shubham Kumar and Vikramdeep Monga* Received: May 02, 2021 Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, Published: June 09, 2021 India © All rights are reserved by Vikramdeep *Corresponding Author: Vikramdeep Monga, Department of Pharmaceutical Monga., et al. Chemistry, ISF College of Pharmacy, Moga, Punjab, India. Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19 or coronavirus disease 2019 and the same has been declared as a global pandemic by WHO which marked the third introduction of a virulent coronavirus into human society. This a threat to human life worldwide. Considerable efforts have been made for developing effective and safe drugs and vaccines against is a highly pathogenic human coronavirus in which pneumonia of unknown origin was identified in China in December 2019 and is SARS-CoV-2. The current situation and progress in the development of various therapeutic candidates including vaccines in preclini- cal and clinical studies have been described in the manuscript. Until now, many people have been infected with this lethal virus, and a lot of people have died from this COVID-19. This viral disease spreads by coming in contact with an infected person. Understand- ing of SARS-CoV-2 is growing in relation to its epidemiology, virology, and clinical management strategies. Till date, very few drugs or vaccines have been developed or approved for the treatment of this deadly disease of COVID-19 and many candidates are under the clinical development pipeline.
    [Show full text]
  • Bjpworker Shot PM Modi Chairs CCS Meeting to Dead by Militants in Cases, One Death Review Situation in Afghanistan JAMMU RISING Gus) in the Union Territory
    JAMMU, WEDNESDAY, AUGUST 18, 2021 JAMMU RISING NEWS P-3 NEWS P-5 NEWS P-12 NATIONAL P-8 SPORT P-7 Advisor 9 Doda youth 36 Keralites T20 World Cup: Bhatnagar get Ramban Admin felicitates DPO stranded in Kabul conducts commercial ICC releases with ‘EX- seek urgent help to vehicles schedule, India- extensive CELLENT return home; CM tour of under Pakistan match CIVILSER- reaches out to Jammu MUMKIN VICES AWARD’ on October 24 city scheme Centre Price: Rs.1 | Page 12 | Vol. No.: 11 | Issue No: 191 Postal Registration No. JK-458/16-18 epaper.dailyjammurising.in RNI No: JKENG/2011/40494 BRIEF NEWS J&K reports 83 COVID-19 BJPworker shot PM Modi chairs CCS meeting to dead by militants in cases, one death review situation in Afghanistan JAMMU RISING gus) in the union territory. The Bulletin also informs J&K’s Kulgam JAMMU, AUG 17 The Government on Tues- that no new confirmed case ABJP worker was shot dead NEW DELHI,AUG 17 tional status of Kabul airport. Jammu and Kashmir day informed that 83 new of Mucormycosis has been by militants in Brazloo area of Prime Minister Narendra This has been discussed at recorded 83 fresh COVID- positive cases of novel reported today, thus the total South Kashmir’s Kulgam dis- Modi chaired a meeting of high levels with our partners, 19 cases and one fatality on Corona virus (COVID-19), number of confirmed cases trict today. the Cabinet Committee on including by EAM with the Tuesday, pushing the union 38 from Jammu division and remains 42 in the UT of Militants fired upon BJP In- Security on Tuesday to re- US Secretary of State.
    [Show full text]
  • Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines
    Review Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines Puna Maya Maharjan 1 and Sunghwa Choe 2,3,* 1 G+FLAS Life Sciences, 123 Uiryodanji-gil, Osong-eup, Heungdeok-gu, Cheongju-si 28161, Korea; punamaya.maharjan@gflas.com 2 G+FLAS Life Sciences, 38 Nakseongdae-ro, Gwanak-gu, Seoul 08790, Korea 3 School of Biological Sciences, College of Natural Sciences, Seoul National University, Gwanak-gu, Seoul 08826, Korea * Correspondence: [email protected] Abstract: The prevalence of the coronavirus disease 2019 (COVID-19) pandemic in its second year has led to massive global human and economic losses. The high transmission rate and the emergence of diverse SARS-CoV-2 variants demand rapid and effective approaches to preventing the spread, diagnosing on time, and treating affected people. Several COVID-19 vaccines are being developed using different production systems, including plants, which promises the production of cheap, safe, stable, and effective vaccines. The potential of a plant-based system for rapid production at a commercial scale and for a quick response to an infectious disease outbreak has been demonstrated by the marketing of carrot-cell-produced taliglucerase alfa (Elelyso) for Gaucher disease and tobacco- produced monoclonal antibodies (ZMapp) for the 2014 Ebola outbreak. Currently, two plant-based COVID-19 vaccine candidates, coronavirus virus-like particle (CoVLP) and Kentucky Bioprocessing (KBP)-201, are in clinical trials, and many more are in the preclinical stage. Interim phase 2 clinical Citation: Maharjan, P.M.; Choe, S. trial results have revealed the high safety and efficacy of the CoVLP vaccine, with 10 times more Plant-Based COVID-19 Vaccines: neutralizing antibody responses compared to those present in a convalescent patient’s plasma.
    [Show full text]
  • Edical Sciences Esearch (IJAMSCR)
    Dr. N. Sriram et al / Int. J. of Allied Med. Sci. and C lin. Research Vol-9(1) 2021 [ 1-10] International Journal of Allied Medical Sciences and Clinical Research (IJAMSCR) ISSN: 2347 -6567 IJAMSCR |Volume 9 | Issue 1 | Jan - Mar - 2021 www.ijamscr.com Review article Medical research Development of new covid -19 vaccines from india : A systematic review 1Dr. N. Sriram, 2S. Kameshwaran , 3Asokkumar DS , 4N. Elavarasan, 5M. Sarbudeen 1Department of Pharmaceutics, Hits College of Pharmacy, Bogaram, Ghatkesar, Hyderabad, Telangana, India 2-5 Excel college of Pharmacy, Komarapalayam, Namakkal, Tamilnadu – 637303. *Corresponding Author :Dr. N. Sriram email: [email protected] ABSTRACT Extreme acute respiratory syndrome Coronavirus 2 (SARS -CoV-2) is an extremely pathogenic new virus that has triggered the current worldwide coronavirus disease pandemic (COVID -19). Currently, substantial effort has been made to produce successful and safe medicines and SARS-CoV-2 vaccines. To avoid more morbidity and death, a successful vaccine is important. Though some regions which deploy COVID -19 vaccines on the basis of protection and immunogenicity data alone, the aim of vaccine research is to obtain d irect proof of vaccine effectiveness in protecting humans against SARS-CoV -2 and COVID-19 infections in order to selectively increase the production of effective vaccines. A SARS-CoV-2 candidate vaccine can function against infection, illness, or transmiss ion and a vaccine that is capable of minimising all of these components may lead to disease control. In this study, we discussed the Bharat Biotech and Covishield Serum Institute of India's Covaxin - India's First Indigenous Covid -19 Vaccine.
    [Show full text]
  • BANCOVID, the First D614G Variant Mrna-Based Vaccine Candidate Against SARS
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.29.319061; this version posted September 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. 1 BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS- 2 CoV-2 elicits neutralizing antibody and balanced cellular immune response 3 Juwel Chandra Baray, Md. Maksudur Rahman Khan, Asif Mahmud, Md. Jikrul Islam, Sanat 4 Myti, Md. Rostum Ali, Md. Enamul Haq Sarker, Samir Kumar, Md. Mobarak Hossain 5 Chowdhury, Rony Roy, Faqrul Islam, Uttam Barman, Habiba Khan, Sourav Chakraborty, Md. 6 Manik Hossain, Md. Mashfiqur Rahman Chowdhury, Polash Ghosh, Mohammad Mohiuddin, 7 Naznin Sultana*, Kakon Nag* 8 Globe Biotech Ltd., 3/Ka, Tejgaon I/A, Dhaka – 1208, Bangladesh, 9 *, to whom correspondence should be made. 10 E-mail: [email protected], [email protected] 11 12 13 Key words: COVID, Coronavirus, Lipid nanoparticle, LNP, Vaccination, Immunization, 14 15 16 Abstract 17 Effective vaccine against SARS-CoV-2 is the utmost importance in the current world. More 18 than 1 million deaths are accounted for relevant pandemic disease COVID-19. Recent data 19 showed that D614G genotype of the virus is highly infectious and responsible for almost all 20 infection for 2nd wave. Despite of multiple vaccine development initiatives, there are currently 21 no report that has addressed this critical variant D614G as vaccine candidate. Here we report 22 the development of an mRNA-LNP vaccine considering the D614G variant and 23 characterization of the vaccine in preclinical trial.
    [Show full text]
  • 1. Sars-Cov Nucleocapsid Protein Epitopes and Uses Thereof
    www.engineeringvillage.com Citation results: 500 Downloaded: 4/24/2020 1. SARS-COV NUCLEOCAPSID PROTEIN EPITOPES AND USES THEREOF KELVIN, David; PERSAD, Desmond; CAMERON, Cheryl; BRAY, Kurtis, R.; LOFARO, Lori, R.; JOHNSON, Camille; SEKALY, Rafick-Pierre; YOUNES, Souheil-Antoine; CHONG, Pele Assignee: UNIVERSITY HEALTH NETWORK; BECKMAN COULTER, INC.; UNIVERSITE DE MONTREAL; NATIONAL HEALTH RESEARCH INSTITUTES Publication Number: WO2005103259 Publication date: 11/03/2005 Kind: Patent Application Publication Database: WO Patents Compilation and indexing terms, 2020 LexisNexis Univentio B.V. Data Provider: Engineering Village 2. SARS-CoV-specific B-cell epitope and applications thereof Wu, Han-Chung; Liu, I-Ju; Chiu, Chien-Yu Assignee: National Taiwan University Publication Number: US20060062804 Publication date: 03/23/2006 Kind: Utility Patent Application Database: US Patents Compilation and indexing terms, 2020 LexisNexis Univentio B.V. Data Provider: Engineering Village 3. A RECOMBINANT SARS-COV VACCINE COMPRISING ATTENUATED VACCINIA VIRUS CARRIERS QIN, Chuan; WEI, Qiang; GAO, Hong; TU, Xinming; CHEN, Zhiwei; ZHANG, Linqi; HO, David, D. Assignee: INSTITUTE OF LABORATORY ANIMAL SCIENCE OF CHINESE ACADEMY OF MEDICAL SCIENCES; THE AARON DIAMOND AIDS RESEARCH CENTER; QIN, Chuan; WEI, Qiang; GAO, Hong; TU, Xinming; CHEN, Zhiwei; ZHANG, Linqi; HO, David, D. Publication Number: WO2006079290 Publication date: 08/03/2006 Kind: Patent Application Publication Database: WO Patents Compilation and indexing terms, 2020 LexisNexis Univentio B.V. Data
    [Show full text]
  • Mrna-Based Vaccines to Elicit CD8+ T Cell Immunity
    mRNA-based Vaccines to Elicit CD8+ T Cell Immunity Ans De Beuckelaer Thesis submitted in partial fulfilment of the requirements for the degree of Doctor in Sciences: Biochemistry and Biotechnology 2016 Promoter Prof. Dr. Johan Grooten Co-promoter Dr. Stefaan De Koker Laboratory of Molecular Immunology Department of Biomedical Molecular Biology Faculty of Sciences, Ghent University The research described in this doctoral thesis was performed at the Department of Biomedical Molecular Biology, Faculty of Sciences, Ghent University. Ans De Beuckelaer was supported by a personal fellowship of the IWT (Innovation by Science and Technology). No part of this thesis may be reproduced or published without prior permission of the author. © Ans De Beuckelaer 2016 mRNA- based Vaccines to Elicit CD8+ T cell Immunity Ans De Beuckelaer1 Academic year: 2015- 2016 Promoter: Prof. Dr. Johan Grooten1 Co-Promoter: Dr. Stefaan De Koker2 Examination committee Chair Prof. Dr. Rudi Beyaert1,3 Secretary Prof. Dr. Xavier Saelens1,4 Voting members Prof. Dr. Vanham5,6 Prof. Dr. Karine Breckpot7 Prof. Dr. Katrien Remaut8 1 Department of Biomedical Molecular Research, Ghent University, Ghent, Belgium 2 eTheRNA Immunotherapeutics NV, Niel, Belgium 3 Inflammation Research Center, VIB, UGhent, Ghent, Belgium 4 Medical Biotechnology, VIB, UGhent, Ghent, Belgium 5 Department of Biomedical Sciences, University of Antwerp, Anwterp, Belgium 6 Department of Biomedical Sciendes, Virology Unit, Institute of Tropical Medicine, Antwerp, Belgium 7 Laboratory of Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Univ. Brussel, Brussels, Belgium 8 Laboratory for General Biochemistry and Physical Pharmacy, Faculty of Pharaceutical Sciences, UGhent, Ghent, Belgium TABLE OF CONTENT List of Abbreviations 8 Summary 13 Samenvatting 17 Introduction 21 CHAPTER 1.
    [Show full text]
  • En Este Número
    Boletín Científico No. 18 (1-10 julio/2021) EN ESTE NÚMERO VacCiencia es una publicación dirigida a Resumen de candidatos vacu- investigadores y especialistas dedicados a nales contra la COVID-19 ba- la vacunología y temas afines, con el ob- sadas en la plataforma de sub- jetivo de serle útil. Usted puede realizar unidad proteica en desarrollo a sugerencias sobre los contenidos y de es- nivel mundial. (segunda parte) ta forma crear una retroalimentación Artículos científicos más que nos permita acercarnos más a sus recientes de Medline sobre necesidades de información. vacunas. Patentes más recientes en Patentscope sobre vacunas. Patentes más recientes en USPTO sobre vacunas. 1| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS Resumen de vacunas contra la COVID-19 basadas en la plataforma de subunidad proteica en desarrollo a nivel mundial (segunda parte) Las vacunas de subunidades antigénicas son aquellas en las que solamente se utilizan los fragmentos específicos (llamados «subunidades antigénicas») del virus o la bacteria que es indispensable que el sistema inmunitario reconozca. Las subunidades antigénicas suelen ser proteínas o hidratos de carbono. La mayoría de las vacunas que figuran en los calendarios de vacunación infantil son de este tipo y protegen a las personas de enfermedades como la tos ferina, el tétanos, la difteria y la meningitis meningocócica. Este tipo de vacunas solo incluye las partes del microorganismo que mejor estimulan al sistema inmunitario. En el caso de las desarrolladas contra la COVID-19 contienen generalmente, la proteína S o fragmentos de la misma como el Dominio de Unión al Receptor (RBD, por sus siglas en inglés).
    [Show full text]
  • INTERNATIONAL STUDENT COVID VACCINE LIST and COMMUNICATION Dear International Student
    INTERNATIONAL STUDENT COVID VACCINE LIST and COMMUNICATION Dear International Student We have provided a list of Selected Countries to help you find the COVID-19 vaccine you may have already received. Please see the “WHO” list below to find your COVID-19 vaccine, and if it has been APPROVED. And please upload your record following these directions: https://youtu.be/wvBGeRqIMHc If you see that your vaccine HAS NOT yet been approved by “WHO”, you may be required to receive an approved COVID-19 vaccine and upload those records to meet UC campus policy and requirements. Many US Airports are now providing COVID-19 vaccine on-site. Here is a list of several California Airports that you may arriving where you may receive a vaccine IMMEDIATELY upon your entry into the U.S. LAX – Los Angeles https://www.flylax.com/TravelSafely SNA – Orange County https://hoagurgentcare.com/airport/ SFO – San Francisco https://www.flysfo.com/travel-well/vaccination-site-sfo If you have any additional questions or concerns, please call (949)824-2300 for support. THANK YOU for helping to ensure UCI continues to be a SAFE and HEALTHY Campus! Dr Chang INDIA SOUTH KOREA TAIWAN INDONESIA VIETNAM JAPAN Vaccine Vaccine Vaccine Vaccine Vaccine Vaccine Oxford–AstraZeneca Oxford-AstraZeneca Sinovac Sputnik V Pfizer–BioNTech Covishield Pfizer–BioNTech Oxford–AstraZeneca Oxford–AstraZeneca Sinopharm Janssen Sinopharm Moderna Pfizer–BioNTech Moderna Pfizer–BioNTech Moderna Moderna Covaxin Novavax Moderna Johnson & Johnson Oxford–AstraZeneca Sputnik V Novavax Nanocovax Johnson & Johnson Sputnik V COVIVAC Sputnik V CanSino Vabiotech MVC-COV1901 ZyCoV-D Corbevax Covovax .
    [Show full text]
  • Coronavirus: Quello Che C'è Da Sapere – 7 Giugno 2021
    Coronavirus: quello che c’è da sapere – 7 giugno 2021 Sommario Quando è iniziata l’epidemia? ...................................................................2 Come viene diagnosticata la malattia Covid-19? ...................................23 Quando è arrivata in Italia? .......................................................................2 Che cosa sono i test sierologici? a cosa servono? ................................25 A cosa è dovuta l’infezione? .....................................................................2 Chi viene colpito dalla malattia Covid-19? ............................................25 Quanto è diffusa l’epidemia? ....................................................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................25 Che cosa sono i coronavirus? ...................................................................2 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....29 Qual è l’origine del virus? .........................................................................4 Il virus può mutare? ..................................................................................4 Esiste un vaccino? ...................................................................................31 Come si trasmette l’infezione? .................................................................9 Quali sono le terapie disponibili?............................................................46 I bambini sono più soggetti all’infezione? .............................................13
    [Show full text]